Zobrazeno 1 - 10
of 271
pro vyhledávání: '"Hajime KATO"'
Publikováno v:
Endocrinology and Metabolism, Vol 39, Iss 2, Pp 255-261 (2024)
Fibroblast growth factor 23 (FGF23) is a pivotal humoral factor for the regulation of serum phosphate levels and was first identified in patients with autosomal dominant hypophosphatemic rickets and tumor-induced osteomalacia (TIO), the most common f
Externí odkaz:
https://doaj.org/article/2ffc0a7928b944bd90a7d94c9db6e4ef
Autor:
Hajime Kato, Soichiro Kimura, Maho Taguchi, Takashi Sunouchi, Yoshitomo Hoshino, Naoko Hidaka, Nadia Edvige Foligno, Minae Koga, Katsunori Manaka, Hiroyuki Tamiya, Masanori Kawakami, Hidenori Kage, Yoichi Yasunaga, Masaomi Nangaku, Noriko Makita, Nobuaki Ito
Publikováno v:
Endocrine Journal, Vol 70, Iss 10, Pp 1005-1013 (2023)
Although there are a few case reports of patients with small cell lung cancer developing hypophosphatemia, detailed information on this condition is scarce. A 52-year-old patient with advanced stage small cell lung cancer developed hypophosphatemia (
Externí odkaz:
https://doaj.org/article/7ade78ff506a45c8a2c319c6c50529f4
Autor:
Naoko Hidaka, Hiroaki Murata, Kanako Tachikawa, Keiichi Osaki, Takashi Sekiyama, Yuka Kinoshita, Hajime Kato, Yoshitomo Hoshino, Soichiro Kimura, Takashi Sunouchi, So Watanabe, Masaomi Nangaku, Noriko Makita, Toshimi Michigami, Nobuaki Ito
Publikováno v:
JBMR Plus, Vol 7, Iss 12, Pp n/a-n/a (2023)
ABSTRACT Hypophosphatasia (HPP) is an inherited disease caused by variants of the ALPL gene encoding tissue‐nonspecific alkaline phosphatase. Adult‐onset HPP (adult HPP), known as a mild form of HPP, develops symptoms involving osteomalacia after
Externí odkaz:
https://doaj.org/article/e4e7ba481e4042fd82c6fe0dd3330d46
Autor:
Yusuke Tsuda, Yoichi Yasunaga, Masanobu Abe, Kazuto Hoshi, Nobuaki Ito, Kenji Kondo, Koichi Okajima, Liuzhe Zhang, Hajime Kato, Naoko Hidaka, Sakae Tanaka, Hiroshi Kobayashi
Publikováno v:
Oral and Maxillofacial Surgery Cases, Vol 9, Iss 4, Pp 100335- (2023)
Objectives: We aimed to report the surgical outcomes of phosphaturic mesenchymal tumors causing tumor-induced osteomalacia in the head and neck. Methods: This study analyzed nine patients who underwent surgical excision of phosphaturic mesenchymal tu
Externí odkaz:
https://doaj.org/article/f153879475a24d99be27f4200fa6827e
Autor:
Hajime Kato, Hiromi Miyazaki, Takehide Kimura, Yoshitomo Hoshino, Naoko Hidaka, Minae Koga, Masaomi Nangaku, Noriko Makita, Nobuaki Ito
Publikováno v:
Bone Reports, Vol 18, Iss , Pp 101659- (2023)
While the positive association between automated intact fibroblast growth factor (FGF) 23 measurement kit (Determinar CL FGF23 [CL]) and the former assay (Kainos [KI]), and clinical utility of CL was well established, the clinical performance of Medf
Externí odkaz:
https://doaj.org/article/14d5828947fa4cd498b80311e39904f3
Autor:
Yoshitomo Hoshino, Naoko Hidaka, Hajime Kato, Minae Koga, Yuki Taniguchi, Hiroshi Kobayashi, Masaomi Nangaku, Noriko Makita, Nobuaki Ito
Publikováno v:
Bone Reports, Vol 17, Iss , Pp 101628- (2022)
Some previous case reports have implied a relationship between acromegaly and ossification of the spinal ligaments. However, there have been no reports of a case series exploring the incidence of ossification of the spinal ligaments in patients with
Externí odkaz:
https://doaj.org/article/390415680e8847e9a04c45d205543282
Autor:
Hajime Kato, Naoko Hidaka, Minae Koga, Yuka Kinoshita, Noriko Makita, Masaomi Nangaku, Nobuaki Ito
Publikováno v:
Bone Reports, Vol 16, Iss , Pp 101163- (2022)
Hypophosphatasia (HPP) is a congenital disorder with decreased activity of tissue-nonspecific alkaline phosphatase. Asfotase alfa is the only treatment approved for HPP and improves the impairment of bone mineralization. Although several previous stu
Externí odkaz:
https://doaj.org/article/3cb220d702114106b4f6e044e00b971f
Autor:
Naoko Hidaka, Hajime Kato, Minae Koga, Masaki Katsura, Yuko Oyama, Yuka Kinoshita, Seiji Fukumoto, Noriko Makita, Masaomi Nangaku, Nobuaki Ito
Publikováno v:
Bone Reports, Vol 15, Iss , Pp 101144- (2021)
Context: Fibroblast growth factor (FGF) 23 is a hormone that regulates serum phosphate levels, the excess action of which causes chronic hypophosphatemic rickets/osteomalacia. To date, there are only two identified causes of acquired FGF23-related hy
Externí odkaz:
https://doaj.org/article/00a1052a4c4246d08fbeed439348eeec
Publikováno v:
Bone Reports, Vol 14, Iss , Pp 100845- (2021)
Externí odkaz:
https://doaj.org/article/8526ff47d37a4e5887767ef67dfd2867
Autor:
Hajime Kato, Naoko Hidaka, Minae Koga, Yuka Kinoshita, Masaomi Nangaku, Noriko Makita, Nobuaki Ito
Publikováno v:
International Journal of Endocrinology, Vol 2021 (2021)
Background. Asfotase alfa is the only approved treatment that can normalize mineralization in patients with hypophosphatasia (HPP). Its interference in alkaline phosphatase (ALP) dependent immunoassays has been reported. Objective. To describe thyroi
Externí odkaz:
https://doaj.org/article/73547560ca6e44ce9147ca2ce1527396